Viridian Therapeutics

miRagen Therapeutics was founded in 2007 with the aim of improving patients' lives by developing innovative microRNA (miRNA)-based treatments for cardiovascular and muscle diseases. On October 28, 2020, Miragen Therapeutics, Inc. completed the acquisition of Viridian Therapeutics, Inc. On January 29, 2021, Miragen Therapeutics, Inc. announced the company name change to Viridian Therapeutics, Inc., effective January 30, with its stock trading symbol on Nasdaq changing from MGEN to VRDN. Viridian Therapeutics is a biotechnology company dedicated to providing new treatment options for patients suffering from serious diseases with currently insufficient therapeutic solutions. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody being developed for the treatment of Thyroid Eye Disease (TED).